Pharmaceuticals News and Research

RSS

McKesson third quarter revenues increase 1% to $31.2 billion

McKesson Corporation today reported that revenues for the third quarter ended December 31, 2012 were $31.2 billion, up 1% compared to $30.8 billion a year ago. On the basis of U.S. generally accepted accounting principles, third-quarter earnings per diluted share was $1.24 compared to $1.20 a year ago.

31 Jan 2013

Teva terminates collaboration with CureTech

Teva Pharmaceutical Industries Ltd. announced today the termination of its collaboration with CureTech Ltd.

31 Jan 2013

No added benefit from linagliptin in patients with type 2 diabetes

Linagliptin has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes. The assessment of the new dossier according to the German Act on the Reform of the Market for Medicinal Products (AMNOG) again showed that no added benefit of the drug over the appropriate comparator therapy (ACT) can be determined, because the pharmaceutical company has not submitted any relevant studies.

31 Jan 2013

Kemwell Biopharma’s Oral Solids manufacturing facility completes USFDA inspection

Kemwell Biopharma Pvt. Ltd., a global pharmaceutical contract development and manufacturing company, announced today that its Oral Solids manufacturing facility located in Bangalore, India has successfully completed a U.S. Food and Drug Administration (USFDA) inspection.

31 Jan 2013

Silibinin kills skin cells mutated by UVA radiation and protects against cancer

A pair of University of Colorado Cancer Center studies published this month show that the milk thistle extract, silibinin, kills skin cells mutated by UVA radiation and protects against damage by UVB radiation - thus protecting against UV-induced skin cancer and photo-aging.

31 Jan 2013

Retired Jackson Laboratory scientist wins two major international science awards

Douglas Coleman, Ph.D., a retired Jackson Laboratory scientist whose work established the first clues to a genetic component in obesity, has won two major international science awards: the Frontiers of Knowledge Award in Biomedicine from the BBVA Foundation, based in Bilbao, Spain, and the King Faisal International Prize in Medicine from the Saudi Arabian King Faisal Foundation.

31 Jan 2013

No added benefit from perampanel in patients with epileptic fits

The drug perampanel has been approved since July 2012 as adjunctive therapy for adults and children aged 12 years and older with epileptic fits (seizures).

30 Jan 2013

Tributyltin exposure may cause ‘transgenerational obesity’

Research shows that offspring of mice exposed to low doses of the chemical tributyltin, used in paints, plastics, and other consumer products, have greater than normal body fat, liver fat, and fat-specific gene expression.

30 Jan 2013

Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.

From QIAGEN Manchester Limited 30 Jan 2013

Molecular genetics expert wins Wolf Prize for his contribution to humanity

Joachim Messing, among the world's top experts in molecular genetics, became famous for developing a genetic engineering technique used in laboratories to create plants that have produced disease-resistant crops considered vital to feeding the world's population.

30 Jan 2013

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Merck Serono, a division of Merck, Darmstadt, Germany, and The Feinstein Institute for Medical Research, announced today that they will collaborate to develop antibodies for the treatment of systemic lupus erythematosus (SLE).

30 Jan 2013

Researchers determine precise configuration of humulones

Researchers employing a century-old observational technique have determined the precise configuration of humulones, substances derived from hops that give beer its distinctive flavor.

30 Jan 2013

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.

30 Jan 2013

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMROTM (mipomersen sodium) injection.

30 Jan 2013

Glenmark third quarter consolidated revenue increases 33.96% to Rs. 13812.59M

Glenmark Pharmaceuticals Limited (GPL), the research-led global integrated pharmaceutical company announced its results for the third quarter ended December 31, 2012.

30 Jan 2013

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS).

30 Jan 2013

Enterprise Ireland welcomes Irish Minister to its pavilion at Arab Health 2013

Enterprise Ireland Dubai, the regional arm of the Irish government organisation responsible for the development and growth of Irish enterprises in world markets, welcomed Minister Costello TD, Irish Minister of State for Trade and Development to its pavilion at this year's Arab Health exhibition.

30 Jan 2013

Sanofi introduces LeGoo gel to temporarily stop blood flow during cardiovascular surgery

Sanofi US announced the commercial launch of LeGoo, a biopolymer gel that allows surgeons to temporarily stop blood flow during surgery without the use of clamps, elastic loops or other conventional occlusion devices, which may increase risk of trauma to blood vessels.

30 Jan 2013

AACN 2013 National Teaching Institute & Critical Care Exposition to be held in Boston

The American Association of Critical-Care Nurses (AACN) invites nurses and other healthcare professionals who care for high acuity and critically ill patients and their families to its 2013 National Teaching Institute & Critical Care Exposition (NTI) in Boston May 20-23, with preconferences May 18-19.

29 Jan 2013

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

29 Jan 2013